Switch theme
Sign up to access all valuation multiples
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
1970
3.9K+
LTM Revenue $1.3B
LTM EBITDA $268M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Conmed has a last 12-month revenue of $1.3B and a last 12-month EBITDA of $268M.
In the most recent fiscal year, Conmed achieved revenue of $1.3B and an EBITDA of $272M.
Conmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Conmed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | XXX | XXX | XXX |
| Gross Profit | $571M | $676M | XXX | XXX | XXX |
| Gross Margin | 46% | 52% | XXX | XXX | XXX |
| EBITDA | $192M | $272M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 21% | XXX | XXX | XXX |
| Net Profit | -$80.6M | $64.5M | XXX | XXX | XXX |
| Net Margin | -6% | 5% | XXX | XXX | XXX |
| Net Debt | $1.0B | $950M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Conmed's stock price is $51.
Conmed has current market cap of $1.6B, and EV of $2.5B.
See Conmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $1.6B | XXX | XXX | XXX | XXX | $4.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Conmed has market cap of $1.6B and EV of $2.5B.
Conmed's trades at 1.9x LTM EV/Revenue multiple, and 9.2x LTM EBITDA.
Analysts estimate Conmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Conmed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | XXX | XXX |
| P/E | 11.9x | XXX | XXX | XXX |
| P/E/Growth | 1.5x | XXX | XXX | XXX |
| EV/FCF | 16.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpConmed's NTM/LTM revenue growth is 4%
Conmed's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Conmed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Conmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Conmed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Conmed acquired XXX companies to date.
Last acquisition by Conmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Conmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Conmed founded? | Conmed was founded in 1970. |
| Where is Conmed headquartered? | Conmed is headquartered in United States of America. |
| How many employees does Conmed have? | As of today, Conmed has 3.9K+ employees. |
| Who is the CEO of Conmed? | Conmed's CEO is Mr. Patrick J. Beyer. |
| Is Conmed publicy listed? | Yes, Conmed is a public company listed on NYS. |
| What is the stock symbol of Conmed? | Conmed trades under CNMD ticker. |
| When did Conmed go public? | Conmed went public in 1987. |
| Who are competitors of Conmed? | Similar companies to Conmed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Conmed? | Conmed's current market cap is $1.6B |
| What is the current revenue of Conmed? | Conmed's last 12-month revenue is $1.3B. |
| What is the current EBITDA of Conmed? | Conmed's last 12-month EBITDA is $268M. |
| What is the current EV/Revenue multiple of Conmed? | Current revenue multiple of Conmed is 1.9x. |
| What is the current EV/EBITDA multiple of Conmed? | Current EBITDA multiple of Conmed is 9.2x. |
| What is the current revenue growth of Conmed? | Conmed revenue growth between 2023 and 2024 was 5%. |
| Is Conmed profitable? | Yes, Conmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
